Deepa Srinivasan
Internal Medicine · Redwood City, CANPI 1326214545
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,474 and has fallen 67.5% since, to $479 in 2023.
Across 115 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$495
- AbbVie$308
- AstraZeneca$278
- Esperion Therapeutics, Inc.$148
- Boehringer Ingelheim$145
- Biohaven Pharmaceutical Holding Company Ltd.$113
- plus $817 from 16 others
What the payments were for
- Food & beverage$2,303100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 32 | $495 |
| AbbVie(2 entities) | 20 | $308 |
| AstraZeneca | 11 | $278 |
| Esperion Therapeutics, Inc. | 2 | $148 |
| Boehringer Ingelheim | 3 | $145 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $113 |
| Sanofi-aventis U.S. LLC | 5 | $106 |
| Lilly USA, LLC | 4 | $91 |
| GSK | 4 | $86 |
| Arbor Pharmaceuticals, Inc. | 6 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $70 |
| Dexcom, Inc. | 3 | $70 |
| Amarin Pharma, Inc. | 3 | $59 |
| Merck | 2 | $45 |
| Novartis | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $31 |
| Dermira, Inc. | 2 | $28 |
| Pfizer | 1 | $22 |
| Abbott | 1 | $22 |
| Amgen | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,303 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 28 | $359 |
| Losartan Potassium | 21 | $290 |
| Metformin Hcl | 21 | $267 |
| Omeprazole | 14 | $228 |
| Metoprolol Succinate | 11 | $221 |
| Amlodipine Besylate | 32 | $205 |
| Tamsulosin Hcl | 11 | $204 |
| Rosuvastatin Calcium | 13 | $174 |
| Simvastatin | 11 | $107 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Redwood City
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.